Dr. John Mcmurray: New And Emerging Heart Failure Therapies

Dr. John McMurray: New and emerging heart failure therapies

Ted Rogers Centre for Heart Research

Professor John McMurray - Heart failure therapy – extending the limits!

At the Limits - Leading Medical Education

SGLT2 Inhibitors in Heart Failure Management with Dr. John McMurray

Prof. John McMurray - What have we learned from the SGLT2i trials in heart failure?

Professor John McMurray - Heart failure: pharmacology that extends the limits!

At the Limits - Leading Medical Education

Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Diabetics and Non-Diabetics

Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023

ESMA CME Channel

Dr. McMurray discusses the DAPA-HF trial of dapagliflozin in systolic heart failure

Behind the Heart | Prof John McMurray

Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure

HF 2022: Heart Failure Highlights of 2022 with Prof John Cleland

Revolutionary Perspectives in Heart Failure: A 45 - Year Journey

Cardiology University of Washington

Contemporary Approach to Heart Failure with Reduced Ejection Fraction

Piedmont Heart Institute

AHA 2019: DAPA-HF - Dr Harriette Van Spall & Prof John McMurray

Normal, Heart attack, Heart failure Echo #shorts #echo

Dr Nagendra Thalor MD medicine DM cardiology

Results of DAPA-HF - Dr. John J McMurray

Dr John McMurray: The Next Step for SGLT 2 Inhibitors in Patients with HF Is Implementation

Heart failure with reduced and preserved ejection fraction, pathophysiology and treatment

Armando Hasudungan

Kevin’s fight to beat heart failure